| GlaxoSmithKline AG - Havrix 1440, Injektionssuspension | | 00558 | | 02 | | Havrix 1440 | | Injektionssuspension | | J07BC02 | | Hepatitis A, inaktiviert, ganzes Virus | | 03.09.1993 | | |
| | Composition | | Vaccinum adsorbatum: hepatitis-A-virus inactivatus (HM175) 1440 U. corresp. proteina max. 0.4 µg, aluminii hydroxidum hydricum ad adsorptionem corresp. aluminium 0.5 mg, aminoacida cum phenylalaninum 166 µg, dinatrii phosphas, kalii dihydrogenophosphas, natrii chloridum, kalii chloridum, polysorbatum 20, aqua ad iniectabile, ad suspensionem pro 1 ml corresp. natrium max. 3.6 mg et kalium max. 0.5 mg, residui: neomycini sulfas. | | Packungsbestandteile | | Suspension injectable | | | | | | | | Principe actif | Concentr. | informations additionels |
|---|
| | 1440 U/ml correspond Protéine 0.4 µg/ml | Vaccinum adsorbatum |
| | BAG: Principe actif | Concentr. |
|---|
| | 1440 U |
| | | | Agents auxilliaires | Concentr. |
|---|
| | | | | 166 µg/ml | | Disodium Phosphate | | | Potassium Chlorure | | | Potassium Dihydrogenophosphate | | | Sodium Chlorure | | | | |
| |
| | numéro d'emballage | Taille des présentations | PEF | PP | Cat. | LS | Hors commerce (MedRef) |
|---|
| 002 | | 31.84 | 51.05 | B | LS | Non |
|
|
